• Влияние пероральной и трансдермальной терапии эстрогенами на сексуальную функцию в период ранней постменопаузы
ru К содержанию

Влияние пероральной и трансдермальной терапии эстрогенами на сексуальную функцию в период ранней постменопаузы

HEALTH OF WOMAN. 2017.9(125):122–128

Hugh S. Taylor, MD; Aya Tal, PhD; Lubna Pal, MD; Fangyong Li, MPH; Dennis M. Black, MD; Eliot A. Brinton, MD; Matthew J. Budoff, MD; Marcelle I. Cedars, MD; Wei Du, MS; Howard N. Hodis, MD; Rogerio A. Lobo, MD; JoAnn E. Manson, MD, DrPH; George R. Merriam, MD; Virginia M. Miller, PhD; Frederick Naftolin, MD; Genevieve Neal-Perry, MD, PhD; Nanette F. Santoro, MD; Sherman M. Harman, MD, PhD

Дополнительное исследование: Kronos Early Estrogen Prevention Study (KEEPS)
Опубликовано 28 августа 2017 года.
Сокращенный вариант

1. Graziottin A, Leiblum SR. 2005. Biologicaland psychosocial pathophysiology of female sexual dysfunction during the menopausal transition. J Sex Med. 2(3):133–145. https://doi.org/10.1111/j.1743-6109.2005.00129.x; PMid:16422790

2. Sarrel PM. 1990. Sexualityandmenopause. Obstet Gynecol. 75(4) (suppl):26S–30S. PMid:2179787

3. Blumel JE, Castelo-Branco C, Binfa L et al. 2000. Quality of life after the menopause: a population study. Maturitas. 34(1):17–23. https://doi.org/10.1016/S0378-5122(99)00081-X

4. Castelo-Branco C, Blumel JE, Araya H et al. 2003. Prevalence of sexual dysfunction in a cohort of middle-aged women: influences of menopause and hormone replacement therapy. J Obstet Gynecol. 23(4):426–430. https://doi.org/10.1080/0144361031000120978; PMid:12881088

5. Dennerstein L, Dudley E, Burger H. 2001. Arechanges in sexual functioning during midlife due to aging or menopause? Fertil Steril. 76(3):456–460. https://doi.org/10.1016/S0015-0282(01)01978-1

6. Coelho G, Frange C, Siegler M, Andersen ML, Tufik S, Hachul H. 2015. Menopause transition symptom clusters: sleep disturbances and sexual dysfunction. J Womens Health (Larchmt). 24(11):958–959. https://doi.org/10.1089/jwh.2015.5537; PMid:26555780

7. Dennerstein L, Koochaki P, Barton I, Graziottin A. 2006. Hypoactive sexual desire disorder in menopausal women: a survey of Western European women.?J Sex Med. 3(2):212–222. https://doi.org/10.1111/j.1743-6109.2006.00215.x; PMid:16490014

8. Prairie BA, Scheier MF, Matthews KA, Chang CC, Hess R. 2011. A higher sense of purpose in life is associated with sexual enjoyment in midlife women. Menopause 18(8):839–844. https://doi.org/10.1097/gme.0b013e31820befca; PMid:21659908 PMCid:PMC3181046

9. Nappi RE, Cucinella L. 2015. Advancesin pharmacotherapy for treating female sexual dysfunction. Expert Opin Pharmacother. 16(6):875–887. https://doi.org/10.1517/14656566.2015.1020791; PMid:25732267

10. Nastri CO, Lara LA, Ferriani RA, Rosa-E-Silva AC, Figueiredo JB, Martins WP. 2013. Hormone therapy for sexual function in perimenopausal and postmenopausal women. Cochrane Database Syst Rev. (6):CD009672. https://doi.org/10.1002/14651858.CD009672.pub2

11. Coelingh Bennink HJ. 2004. Are all estrogens the same? Maturitas. 47(4):269-275. Areallestrogensthe. https://doi.org/10.1016/j.maturitas.2003.11.009; PMid:15063479

12. Shifren JL, Desindes S, McIlwain M, Doros G, Mazer NA. 2007. A randomized, open-label, crossover study comparing the effects of oral versus transdermal estrogen therapy on serum androgens, thyroid hormones, and adrenal hormones in naturally menopausal women. Menopause. 14(6):985-994. Areallestrogensthe. https://doi.org/10.1097/gme.0b013e31803867a

13. Hodis HN, Mack WJ, Azen SP et al. 2003. Women’s Estrogen-Progestin Lipid-Lowering Hormone Atherosclerosis Regression Trial Research Group. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N Engl J Med. 349(6):535–545. https://doi.org/10.1056/NEJMoa030830; PMid:12904518

14. Taylor HS, Manson JE. 2011. Updateinhormone therapy use in menopause. J Clin Endocrinol Metab. 96(2):255–264. https://doi.org/10.1210/jc.2010-0536; PMid:21296989

15. Mille VM, Black DM, Brinton EA et al. 2009. Using basic science to design a clinical trial: baseline characteristics of women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). J Cardiovasc Transl Res. 2(3):228–239. https://doi.org/10.1007/s12265-009-9104-y; PMid:19668346 PMCid:PMC2721728

16. Wharton W, Gleason CE, Miller VM, Asthana S. 2013. Rationale and design of the Kronos Early Estrogen Prevention Study (KEEPS) and the KEEPS Cognitive and Affective sub study (KEEPS Cog). Brain Res. 1514:12–17. https://doi.org/10.1016/j.brainres.2013.04.011; PMid:23603409 PMCid:PMC3731133

17. Harman SM, Brinton EA, Cedars M et al. 2005. KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric. 8(1):3–12. https://doi.org/10.1080/13697130500042417; PMid:15804727

18. Chetkowski RJ, Meldrum DR, Steingold KA et al. 1986. Biologic effects of transdermal estradiol. N Engl J Med. 314(25):1615–1620. https://doi.org/10.1056/NEJM198606193142505; PMid:3012339

19. Harman SM, Black DM, Naftolin F et al. 2014. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Ann Intern Med. 161(4):249–260. https://doi.org/10.7326/M14-0353

20. Rosen R, Brown C, Heiman J et al. 2000. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 26(2):191–208. https://doi.org/10.1080/009262300278597; PMid:10782451

21. Meston CM. 2003. Validation of the Female Sexual Function Index (FSFI) in women with female orgasmic disorder and in women with hypoactive sexual desire disorder. J Sex Marital Ther. 29(1):39–46. https://doi.org/10.1080/713847100; PMid:12519665 PMCid:PMC2872178

22. Wiegel M, Meston C, Rosen R. 2005. The female sexual function index (FSFI): cross-validation and development of clinical cutoff scores. J Sex Marital Ther. 31(1):1–20. https://doi.org/10.1080/00926230590475206; PMid:15841702

23. Al-Azzawi F, Bitzer J, Brandenburg U et al. 2010. Therapeutic options for postmenopausal female sexual dysfunction. Climacteric. 13(2):103–120. https://doi.org/10.3109/13697130903437615; PMid:19958161

24. Fitzmaurice GM, Laird NM, Ware JH. 2012. Applied Longitudinal Analysis. New York, NY, John Wiley & Sons.

25. Allison PD. Handling missing data by maximum likelihood. Paper presented at: SAS Global Forum 2012. 2012 April, 22–25. Orlando, Florida. PMid:22127681

26. Addis IB, Van Den Eeden SK, Wassel-Fyr CL, Vittinghoff E, Brown JS, Thom DH. 2006. Reproductive Risk Factors for Incontinence Study at Kaiser Study Group. Sexual activity and function in middle-aged and older women. Obstet Gynecol. 107(4):755–764. https://doi.org/10.1097/01.AOG.0000202398.27428.e2; PMid:16582109 PMCid:PMC1557393

27. Maclennan AH, Broadbent JL, Lester S, Moore V. 2004. Oral oestrogen and combined oestrogen/ progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev. (4):CD002978. https://doi.org/10.1002/14651858.CD002978.pub2

28. Suckling J, Lethaby A, Kennedy R. 2006. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. (4):CD001500. https://doi.org/10.1002/14651858.CD001500.pub2

29. Politano CA, Valadares AL, Pinto-Neto A, Costa-Paiva L. 2015. The metabolic syndrome and sexual function in climacteric women: a cross-sectional study. J Sex Med. 12(2):455–462. https://doi.org/10.1111/jsm.12749; PMid:25441664

30. Merghati-Khoei E, Sheikhan F, Shamsalizadeh N, Haghani H, Yousofnia Pasha YR, Killeen T. 2014. Menopause negatively impacts sexual lives of middle-aged Iranian women: a cross-sectional study. J Sex Marital Ther. 40(6):552–560. https://doi.org/10.1080/0092623X.2013.796577; PMid:24308863

31. Valadares AL, Pinto-Neto AM, de Souza MH, Osis MJ, da Costa Paiva LH. 2011. The prevalence of the components of low sexual function and associated factors in middle-aged women. J Sex Med. 8(10):2851–2858. https://doi.org/10.1111/j.1743-6109.2011.02405.x; PMid:21810185

32. Valadares AL, Pinto-Neto AM, Osis MJ, Sousa MH, Costa-Paiva L, Conde DM. 2008. Prevalence of sexual dysfunction and its associated factors in women aged 40-65 years with 11 years or more of formal education: a population-based household survey. Clinics (Sao Paulo). 63(6):775–782. https://doi.org/10.1590/S1807-59322008000600012; PMCid:PMC2664278

33. Burger HG, Dudley EC, Cui J, Dennerstein L, Hopper JL. 2000. A prospective longitudinal study of serum testosterone, dehydroepiandrosterone sulfate, and sex hormone-binding globulin levels through the menopause transition. J Clin Endocrinol Metab. 85(8):2832–2838. https://doi.org/10.1210/jcem.85.8.6740; https://doi.org/10.1210/jc.85.8.2832

34. Ambler DR, Bieber EJ, Diamond MP. 2012. Sexual function in elderly women: a review of current literature. Rev Obstet Gynecol. 5(1):16–27. PMid:22582123 PMCid:PMC3349920

35. Davison SL, Bell R, Donath S, Montalto JG, Davis SR. 2005. Androgen levels in adult females: changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab. 90(7):3847–3853. https://doi.org/10.1210/jc.2005-0212; PMid:15827095

36. Nappi RE. 2015. To be or not to be in sexual desire: the androgen dilemma. Climacteric. 18(5):672–674. https://doi.org/10.3109/13697137.2015.1064268; PMid:26176767

37. Huang A, Yaffe K, Vittinghoff E et al. 2008. The effect of ultralow-dose transdermal estradiol on sexual function in postmenopausal women. Am J Obstet Gynecol. 198(3):265.e1–265.e7. https://doi.org/10.1016/j.ajog.2007.09.039; PMid:18313446

38. Reay Jones NH, Healy JC, King LJ, Saini S, Shousha S, Allen-Mersh TG. 2003. Pelvic connective tissue resilience decreases with vaginal delivery, menopause and uterine prolapse. Br J Surg. 90(4):466–472. https://doi.org/10.1002/bjs.4065; PMid:12673750

39. Laumann EO, Paik A, Rosen RC. 1999. Sexual dysfunction in the United States: prevalence and predictors. JAMA. 281(6):537–544. https://doi.org/10.1001/jama.281.6.537

40. Nascimento ER, Maia AC, Pereira V, Soares-Filho G, Nardi AE, Silva AC. 2013. Sexual dysfunction and cardiovascular diseases: a systematic review of prevalence. Clinics (Sao Paulo). 68(11):1462–1468. https://doi.org/10.6061/clinics/2013(11)13

41. Alexander JL-KK, Dennerstein L, Davis SR. 2003. The systemic nature of sexual functioning in the postmenopausal woman: crossroads of psychiatry and gynecology. Prim Psychiatry. 10:53–57.

42. Avis NE, Brockwell S, Randolph JF-Jr et al. 2009. Longitudinal changes in sexual functioning as women transition through menopause: results from the Study of Women’s Health Across the Nation. Menopause 16(3):442–452. https://doi.org/10.1097/gme.0b013e3181948dd0; PMid:19212271 PMCid:PMC2908487

43. Gracia CR, Freeman EW, Sammel MD, Lin H, Mogul M. 2007. Hormones and sexuality during transition to menopause. Obstet Gynecol. 109(4):831–840. https://doi.org/10.1097/01.AOG.0000258781.15142.0d; PMid:17400843

44. Derogatis LR, Rosen R, Leiblum S, Burnett A, Heiman J. 2002. The Female Sexual Distress Scale (FSDS): initial validation of a standardized scale for assessment of sexually related personal distress in women. J Sex Marital Ther. 28(4):317–330. https://doi.org/10.1080/00926230290001448; PMid:12082670